事件： 截至 2024 年 6 月 30 日止六个月，实现收益 24.98 亿港元，同比减少 27%；毛利为 14.06 亿港元，同比减少 37%；公司拥有人应占溢利 8.37 亿港元，同比减少 32%；基本每股盈利 17.00 港仙，拟派中期股 息每股普通股 9 港仙。 相关报告 点评观点： ➢ 产量暂时下跌影响单位成本： 上半年公司收入和利润减少主要因为精焦煤量价齐跌加上生产成本 上升。期内精焦煤销量同比下跌 25%、精焦煤的平均实现售价同比下 跌 2%。期内公司原焦煤產量同比下跌 15%，折摊费用增加 30%至 96 元/吨，受此影响，上半年公司原焦煤生产成本增加 53 元/吨至 453 元 /吨，同比增长 13%。 ➢ 明年产量有望恢复至 500-525 万吨： 期内公司原焦煤产量约 225 万吨，同比减少 15%；而因入洗原焦煤产 量减少及回收率下降，精焦煤产量约 129 万吨，同比下跌 31%。因为 公司兴无矿进入下组煤联合试运转，上组煤关闭影响上半年产量，公 司调低 2024 年全年原焦煤产量指引为 480-525 万吨。目前兴无矿下 组煤工程完工并顺利投产，预期明年产量有望恢复至 500-52 ...

证 券 研 究 报 告 | --- | --- | |-----------------------------|--------------------------------------------------------------------------------------| | 即时点评 | 天然气售气量强劲增长，积极扩充风资源储备 | | 新天绿色能源（ 0956 HK ） | 2024-08-29 星期四 | | | 事件： | | | 截至 2024 年 6 月 30 日止六个月， 公司营业收入为人民币 121.37 亿元， | | | 较去年同期增长 20.8% ；归属于上市公司股东的净利润为人民币 14.30 | | | 亿元，较去年同期下降 0.62% ；及基本每股收益为人民币 0.34 元。 | | 相关报告 | 点评观点： | | | ➢ 上半年天然气业务盈利表现良好： | | | 上半年，公司实现净利润 16.82 亿元，同比下降 1.89% ；其中天然气 | | | 业务实现净利润 4.49 亿元，同比增长 44.98% ；新能源业务实现净利 | | | 润 11.64 亿元 ...

| --- | --- | |-------------------------|-----------------------------------------------------------------------------------------------------------------------------| | 即时点评 | 核心产品 IMM01 数据优秀，创新药管线储备丰富 | | 宜明昂科-B（1541.HK） | 2024-08-27 星期二 | | | 事件： | | | 公司公布半年业绩，截至 2024 年 6 月 30 日半年度亏损同比缩窄， | | | 录得股东应占亏损 1.66 亿元，上年同期亏损 1.71 亿元；总营收 7.7 | | | 万元，同比减少 10.47%；每股净资产为 1.6042 元。 | | | 点评观点： | | | ➢ 研发效率提升： | | 相关报告 | 公司是全球少数能够对先天性免疫和适应性免疫系统进行系统性利用的生物技术公司之一。公司 24 年中期研发开支减少，主要因为 1) | | | 临床试验开支减少人民币 11.7 百万元，由于节约 ...

Investment Rating - The report assigns a "Buy" rating to the company with a target price of HKD 8.67, representing a potential upside of 47% from the current price of HKD 5.90 [1][7][14]. Core Insights - The company has demonstrated continuous rapid growth, with a mid-year revenue of RMB 1.269 billion in 2024, reflecting a year-on-year increase of 13.3%, and a net profit of RMB 398 million, up 14.9% year-on-year. Since its listing in 2013, the company has achieved a compound annual growth rate (CAGR) of 16.3% in revenue and 17.8% in net profit, showcasing its strong product and management capabilities [5][9]. - The company focuses on the nephrology and imaging sectors, with a rich pipeline of products including 6 innovative drugs and 6 generic drugs. It has 8 products under development in nephrology, with significant market opportunities [6][13][14]. - The company has a robust financial structure, with cash and cash equivalents reaching RMB 3.581 billion and a reduction in accounts receivable by 8.7% year-on-year, indicating improved operational efficiency [9]. Summary by Sections Financial Performance - For the first half of 2024, the company reported revenue of RMB 1.269 billion, a 13.3% increase year-on-year, and a net profit of RMB 398 million, up 14.9% year-on-year. The company has distributed over HKD 2.4 billion in dividends to shareholders, with a mid-year dividend of HKD 0.30 per share, compared to HKD 0.15 in the same period last year [5][9]. - The company has improved its cash flow management, with accounts receivable turnover days decreasing to 34.7 days, down from 36.3 days in 2023 [9]. Product Competitiveness - The core products in nephrology, including "Uremia Clear" and "Yishen Huashi Granules," generated sales of RMB 883 million, a growth of 11.1% year-on-year, with "Yishen Huashi Granules" sales increasing by 34.7% [6][11]. - The company has expanded its market reach, covering 42,000 medical institutions and 280,000 pharmacies, and has seen a 28.7% increase in revenue from its pediatric and women's health products [6][11]. Market and Industry Context - The Chinese government is strongly supporting the development of traditional Chinese medicine, enhancing the strategic position of the industry. Policies such as the "14th Five-Year Plan for the Development of Traditional Chinese Medicine" are expected to drive growth and standardization in the sector [12].

Investment Rating - The report assigns a stable investment rating to Sinopec Kantons Holdings Limited (0934.HK) based on its consistent dividend policy and cash position [2][3]. Core Insights - The company's mid-year performance for 2024 was below expectations, with a revenue of approximately 331 million HKD, reflecting a year-on-year increase of about 7.29%. However, the net profit attributable to shareholders decreased by approximately 7.90% to 685 million HKD [3]. - The company maintained a stable interim dividend of 10 HKD per share, consistent with the same period in 2023, indicating a commitment to shareholder returns despite fluctuating profits [3]. - The cash and cash equivalents, along with time deposits maturing beyond three months, totaled approximately 6.437 billion HKD as of June 30, 2024, representing a year-on-year growth of about 10.49% [3]. Financial Performance Summary - Total revenue for the years 2020 to 2024H1 shows a slight decline from 601 million HKD in 2020 to 610 million HKD in 2023, with a projected revenue of 331 million HKD for the first half of 2024 [1]. - The net profit attributable to shareholders saw a significant drop from 2.302 billion HKD in 2020 to 435 million HKD in 2022, followed by a recovery to 1.299 billion HKD in 2023, and a projected 685 million HKD for 2024H1 [1]. - Earnings per share (EPS) decreased from 0.9259 HKD in 2020 to 0.1749 HKD in 2022, with a recovery to 0.5223 HKD in 2023 and a projected 0.2757 HKD for 2024H1 [1]. - The dividend per share remained stable at 0.2 HKD from 2020 to 2022, increased to 0.25 HKD in 2023, and is projected to decrease to 0.1 HKD in 2024H1 [1]. Segment Performance Summary - The petrochemical segment showed stable revenue growth, with a total of 57 oil tankers unloaded in the first half of 2024, achieving a crude oil unloading volume of approximately 7.39 million tons, a year-on-year increase of about 23.58% [4]. - The domestic joint venture terminal performance declined by 6.74% in the first half of 2024, attributed to a decrease in crude oil imports and the depreciation of the RMB against the HKD [5]. - The overseas storage business reported a significant increase in investment income, with average rental prices in Fujairah rising by 13%, leading to an investment income of approximately 67.05 million HKD, a year-on-year increase of about 34.67% [6].

即时点评 垃圾焚烧发电存量项目运营稳健 粤丰环保（1381 HK） 2024-08-22 星期四 事件： 公司公告 2024 年上半年业绩，截至 2024 年 6 月 30 日止六个月，集 团收入为 21.304 亿港元，同比减少 28.5%。售电及垃圾处理的收入为 18.191 亿港元，同比增加 4.8%。毛利率为 48.5%。经营利润为 7.957 亿港元。EBITDA 利润率为 62.0%。公司权益持有人应占利润为 4.450 亿港元，同比减少 27.08%。每股基本盈利为 18.3 港仙，经营活动所 相关报告 得现金净额达 6.131 亿港元。 点评观点： ➢ 公司转型成为综合智能城市管理服务提供商： 垃圾焚烧发电业务进入成熟发展阶段，公司转型成为综合智能城市管 理服务提供商。总收入下跌主要由于集团去年仍有建设收入，但该等 项目于去年已投产，期内没有新建项目而不再产生建设收入所致。 ➢ 持续拓展环卫业务，加大协同效应： 2024 年 3 月，公司正式承接了为期 10 年的香港废物转运站合同；并 首次中标垃圾发电项目所在地外的安徽省城市管家服务项目，服务期 限 25 年，合同总额约 18 亿元；中标农村 ...

即时点评 毛利率改善，自有品牌(APV)营收贡献增长 思摩尔国际(6969.HK) 2024-08-21 星期三 事件： 思摩尔国际公布 2024 年中期业绩，公司营收 50.37 亿元人民币，同比 下降 1.7%；毛利为 19.15 亿元人民币，同比增长 3.2%；净利润为 6.83 亿元人民币，同比下降 4.8%。 点评： 自有品牌(APV)贡献增长，毛利率改善： 相关报告 公司自有品牌业务占比上升，报告期收入 11.2 亿元人民币，同比上升 71.9%。其中，欧洲及其他市场上涨较快，同比上升 88%，美国市场同 比上升 20.6%，主要得益于公司全面推行数字化的管理，直达消费者 快速反映市场的需求。公司持续进行成本管理，24H1 公司分销及销售、 行政、研发费用率分别为 7.4%、6.7%、15.1%，同比+3.3pp、-2.4pp、 +3.1pp。分销及销售费用上升主要系公司增加本地化推广和新产品推 广所致；研发费用上升主要系公司加大雾化医疗和加热不燃烧产品的 投入所致。 面向企业客户(ODM)板块有待恢复： 公司面向企业客户报告期收入 39.2 亿元人民币，其中欧洲市场收入同 比下降 16%，美国市 ...

ep 时点 评 7 月骨专家热烈良好，水电大幅落长 中国电力（2380 HK） 2024-08-19 圣期一 李件： 公司公告，基于初步统计，本公司及其附属公司手 2024 年 7 月的合 并总鲁电宣为 12, 243, 061 兆瓦时，较去年同期增加 29, 22%；荷 2024 年首 7 个月的合并总售电量为 76, 587, 215 兆瓦时，较去年同期增加 32. 65%。公司手 2024 年 7 月及栽至 2024 年 7 月 31 日止七个月的总 售电量，技发电厂类型列示如下： 主要财务指标 相关报告 全資擁有或控股 2024 年的發現實 7 月 水力發電2,693,092 風力發電2,221,998 光伏發電2,277,473 燃煤發電4,687,710 天然氣發電230,047 132,741環保發電 合計12,243,061 主要聯督公司或 2024 年 合落公司的發電廠 7 月 風力發電 139,511 光伏發電 22,498 燃煤發電 3,506,180 合計 3,668,189 信電量（兆瓦時） 2024 年2023 年2023 年 同比變化同比變化 7 月首七個月 905,415197 ...

Investment Rating - The report does not explicitly state an investment rating for the company Core Insights - The company's core profit for the first half of 2024 is HKD 3.186 billion, a 2% increase year-on-year, despite total revenue decreasing by 5.76% to HKD 27.496 billion [3] - The urban gas business in mainland China shows steady growth, with gas sales volume increasing by 7% to 18.6 billion cubic meters and the average gas price margin rising to RMB 0.5 per cubic meter [4] - Green energy initiatives, including hydrogen, sustainable aviation fuel, and green methanol, are highlighted as new growth areas for the company [6] Financial Performance Summary - Total revenue (in million HKD) for the years 2020 to 2024H1: 40,927, 53,564, 60,953, 56,971, and 27,496 respectively, with a growth rate of -1.15% for 2024H1 [2] - Net profit attributable to shareholders (in million HKD) for the same period: 6,007, 5,017, 5,248, 6,070, and 3,040 respectively, with a growth rate of 63.2% for 2024H1 [2] - Earnings per share (EPS) for 2024H1 is HKD 0.163, with a mid-year dividend of HKD 0.12 [3] Cash Flow and Capital Expenditure - The company expects total cash inflow of approximately HKD 9 billion for 2024, with HKD 7.5 billion coming from gas operations and asset sales contributing over HKD 1 billion [5] - The management emphasizes controlling capital expenditure and maintaining a stable debt ratio without increasing liabilities to boost dividends [5]

Investment Rating - The report does not explicitly state an investment rating for the company Core Insights - The company has shown significant growth in core profits, with a 57.5% increase in mid-2024 core profits to HKD 707 million, despite a 33.4% decline in shareholder profit [2] - The renewable energy sector has experienced strong growth, with net profits rising to HKD 164 million in H1 2024, compared to HKD 3 million in H1 2023 [3] - The urban gas business has demonstrated steady growth, with gas sales volume increasing by 6% to 8.741 billion cubic meters in H1 2024 [4] Financial Performance Summary - Total revenue for the company in 2023 was HKD 19,842 million, reflecting a slight decrease of 1.15% from 2022 [1] - The net profit attributable to shareholders for 2023 was HKD 1,575 million, marking a significant increase of 63.2% compared to 2022 [1] - Earnings per share (EPS) for 2023 was HKD 0.4774, up from HKD 0.3017 in 2022 [1] - The return on equity (ROE) for 2023 was 6.89%, an improvement from 4.49% in 2022 [1] - The price-to-earnings (PE) ratio for 2023 was 6.81, down from 12.99 in 2022 [1]